Pharmaceutical

Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments

The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with fibrostenosing Crohn’s disease.

Oct 26, 2024 - 04:00
Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments
The funds will be used to advance Agomab’s candidates through clinical trials, including AGMB-129 for patients with fibrostenosing Crohn’s disease.
Read the original article

Tags:

Previous Article

Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline

Next Article

Dyno and Roche collaborate on neurological gene therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: New mega-deal highlights Geisinger’s fall, and raises concerns about where Kaiser is going next

STAT+: New mega-deal highlights Geisinger’s fall, and r...

May 1, 2023

Why CG Oncology will be the first test of 2024’s IPO waters

Why CG Oncology will be the first test of 2024’s IPO wa...

Jan 4, 2024

STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs

STAT+: Pharmalittle: Woodcock to retire from the FDA; A...

Nov 17, 2023